BRAF and colorectal carcinoma: The BRAF inhibition in CRC often leads to the upregulation of receptor tyrosine kinases (RTKs) and their downstream effectors, such as Gab2, which can activate alternative survival pathways and contribute to resistance against BRAF inhibitors [46].